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Anemia is the most common hematological abrnormality in cancer patients. Unfortunately, it is often underrrecognized and underrtreated. 
The pathogenesis of cancerrrelated anemia is complex 
and often multifactorial. While both radiotherapy and 
chemotherapy can be immunosuppressive and inhibit 
erythropoiesis, some treatments cause a greater degree 
of anemia than others.1 A significant portion of cancer 
patients with anemia have no identifiable causes; the 
anemia in this situation is classified as anemia of chronr
ic disease. The underlying mechanisms responsible for 
this type of anemia are unclear, but are thought to inr
volve the activation of cytokines such as interleukinr1 
The impact of recently published negative 
erythropoiesis-stimulating agent studies on 
the clinical management of cancer-related 
anemia at a single center
Hikmat AbdeltRazeq, Shadi Hijjawi, Hazem Abdulelah, Rula Amarin, Majid Asawaeer, Haitham 
Shaheen
from the King hussein cancer center, amman, Jordan
correspondence: hikmat abdel-razeq · King hussein cancer center, po box 1269, amman 11941, Jordan · habdelrazeq@khcc.jo · accepted 
for publication may 2010
hematol oncol stem cell ther 2010; 3(2): 78-83
BACKGROUND AND OBjECTIvES: anemia in cancer patients is common, but often under-recognized and 
under-treated. erythropoiesis stimulating agents (esas) are widely used to prevent and treat cancer and chemo-
therapy-related anemia, but recent studies suggest a negative impact on disease progression and survival associ-
ated with their use. this retrospective study describes the prevalence of anemia in cancer patients and recent 
trends in its management given the negative studies.
PATIENTS AND METHODS: all consecutive adult cancer patients (n=959) admitted to regular medical units 
over one year were reviewed. patients with a hemoglobin (hb) value <12 g/dl on admission were considered 
anemic. information on the primary tumor, main reasons for admission and treatment given were collected. 
RESULTS: at the time of enrollment, anemia was detected in 755 (78.7%) patients. the mean hb value for 
anemic patients was 9.5 g/dl. prevalence and severity of anemia varied according to tumor type and reason for 
admission. the majority (68.6%) of the anemic patients were not offered treatment. the mean hb value at which 
treatment was started was 8.0 g/dl. anemia treatment was related to its severity; treatment rates were 94.4%, 
32.9%, and 5.0% in patients with severe, moderate and mild anemia, respectively (P<.0001). blood transfusion 
was used the most while esas were rarely used. length of hospital stay was affected by the presence of anemia 
(7.2 days in anemic patients vs. 4.85 days in nonanemic patients) (P<.001).
CONCLUSIONS: blood transfusion was used the most for cancer-related anemia, while esas were rarely used. 
the majority of patients with moderate anemia were not treated, including patients on active chemotherapy. 
better guidelines addressing anemia management in this subgroup of patients are highly needed.
and tissue necrosis factor (TNF). These cytokines may 
suppress endogenous erythropoietin (EPO) producr
tion, impair iron utilization and reduce erythroid prer
cursor proliferation.2
Anemia can cause a wide range of symptoms involvr
ing almost every organ. The severity of these symptoms 
depends on several factors such as the degree of anemia, 
rapidity of onset and cormorbidities. These symptoms 
range from dizziness and palpitation to pulmonary eder
ma, heart failure, depression and even cognitive impairr
ment.3 Fatigue, a common symptom in cancer patients, 
is considered an important factor that adversely affects 
the quality of life (QOL) in such patients.4,5 While 
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cancer fatigue has different pathogenetic mechanisms, 
anemia is believed to be a significant contributing facr
tor.6 Additionally, there is increasing evidence to suggest 
that anemia is an independent factor that can adversely 
affect survival in cancer patients.7,8
Recombinant human erythropoiesis stimulatr
ing agents (ESAs) have been in use for many years to 
treat anemia associated with cancer and chemotherapy. 
Several studies have demonstrated that ESAs were efr
fective in increasing hemoglobin levels as compared to 
placebo.9r11 However, many recent studies involving par
tients with different kind of cancers at different stages 
of their disease suggest a negative impact on disease 
progression and survival when ESAs were used to keep 
hemoglobin at a higher level.12r18 This report describes 
the prevalence of anemia in cancer patients and recent 
trends in its management at our institution following 
the recent confusion and uncertainties about the safety 
of ESAs in the treatment of anemia in cancer patients. 
PATIENTS AND METHODS
This was a retrospective, descriptive study, conducted 
at King Hussein Cancer Center (KHCC), a Joint 
Commission Internationalraccredited comprehensive 
cancer center in Amman, Jordan. We retrospectively rer
viewed all consecutive adult (≥ 18 years) cancer patients 
(n=959) admitted to regular medical units between 
January and December 2008. Patients were eligible for 
inclusion regardless of their cancer type, stage, treatr
ment or disease status. Patients admitted to leukemia, 
bone marrow transplantation and intensive care units 
were excluded. Information on demographic characterr
istics, reasons for admission, primary cancer diagnosis, 
disease stage and treatment for anemia were collected. 
Based on toxicity grading criteria from the National 
Cancer Institute, anemia was defined as a hemoglobin 
level <12 g/dL. As in many clinical studies of anemia in 
cancer patients, age and gender variation in hemoglobin 
level were not considered in defining anemia. Based on 
this criteria, anemia was further classified as mild (Hb: 
10.0r11.9 g/dL), moderate (Hb: 8.0r9.9 g/dL) and ser
vere (Hb: <8.0 g/dL). 
In addition to presenting information on diagnosis, 
severity and treatment of anemia by counts and percentr
ages, we compared different variables between anemic 
versus nonanemic patients and patients treated for aner
mia versus those not treated. Comparisons of categorir
cal variables were performed using the chirsquare test. 
Length of stay was compared between anemic and nonr
anemic groups using the Wilcoxon rank test. The imr
pact of anemic status, age, stage, primary diagnosis and 
reason for admission on length of stay was tested using 
ANCOVA. ANCOVA assumptions were verified and 
the log transformation was applied to the length of stay 
to satisfy the normality assumption. 
RESULTS
The 959 patients had a mean age (SD) of 53 (16) years 
and 492 (51%) patients were males. Main reasons for 
admission at time of enrollment were chemotherapy in 
217 (22.6%), infections including neutropenic fever in 
190 (19.8%), and palliative and supportive care in 145 
(15.1%). Other reasons for admission were pulmonary, 
neurological, renal and electrolyte imbalances. Primary 
cancer diagnoses were gastrointestinal in 203 (21.2%), 
breast in 154 (16.1%), lymphoma and multiple myelor
ma in 151 (15.7%), and lung in 106 (11.1%). At time 
of enrollment, 54.7% of patients had advancedrstage 
disease. Demographic data and patient characteristics 
at enrollment are presented in Table 1.
Anemia at time of first admission was detected in 
755 (78.7%) patients. The mean hemoglobin value 
for anemic patients was 9.5 g/dL (range 3.5r11.9, mer
dian 9.6). Severe anemia was detected in 126 (16.7%), 
moderate in 319 (42.3%) and mild in 310 (41.1%) 
patients. Prevalence and severity of anemia varied acr
cording to tumor type (Table 2); thyroid cancers and 
unknown primary tumors had the lowest prevalence of 
severe anemia with rates of 0% and 7.7% respectively, 
while lymphoma/multiple myeloma and genitourinary 
tumors were associated with the highest rate of severe 
anemia with rates of 22.1% and 19.7%, respectively. 
Anemia prevalence also varied in relation to reason for 
admission; except for bleeding, severe anemia was obr
served most often among patients admitted with infecr
tions (24.4%) and lowest among patients admitted for 
initial staging and workup (4.8%) (Table 3).
Of the 755 patients who were anemic at enrollment, 
more than tworthirds (518, 68.6%) were not offered 
anemia treatment. However, most (60%) had hemor
globin levels between 10.0 and 11.9 g/dL. The mean 
hemoglobin value at which treatment was started was 
8.0 g/dL, while the mean hemoglobin for the patients 
who were not treated was 10.2 g/dL. Anemia treatment 
was related to severity; 119 (94.4%) patients with ser
vere anemia were treated compared to a treatment rate 
of 32.9% in the group with moderate anemia, and 5.0% 
in patients with mild anemia (P<.0001). Treatment ofr
fered for patients with anemia varied; blood transfur
sion was given to 188 (79.3%), supplements (includr
ing iron, folate and/or vitamin B12) were used in 25 
(10.5%) while ESAs were offered for only 8 (3.4%) of 
the treated patients. Combination therapy was given to 
16 (6.7%) patients (Table 4).
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Table 1.  patient characteristics.
   Age (years)
      Median (range) 55 (18-91)
      Mean (Sd) 53 (16)
   Sex, n (%)
      Male 492 (51.3)
      Female 467 (48.7)
   Disease stage, n (%)
      localized 268 (27.9)
      Metastatic 525 (54.7)
      n/a (including lymphoma and lyeloma) 166 (17.3)
   Tumor type , n (%)
      gastrointestinal-colorectal 203 (21.2)
      Breast 154 (16.1)
      lymphoma/myeloma 151 (15.7)
      lung 106 (11.1)
      genitourinary 77 (8.0 )
      Head and neck 63 (6.6)
      gynecological 48 (5.0)
      Thyroid 43 (4.5)
      Bone and soft tissue sarcoma 42 (4.4)
      Brain 38 (4.4)
      Unknown primary 17 (1.8)
      Others 17 (1.8)
   Reasons for admission, n (%)
      Chemotherapy 217 (22.6)
      infections 190 (19.8)
      Supportive care 145 (15.1)
      neurological 58 (6.0)
      electrolyte imbalance 32 (3.3)
      initial staging work up 28 (2.9)
      procedures 25 (2.6)
      Venous thromboembolism 24 (2.5)
      gastrointestinal 20 (2.1)
      respiratory 63 (6.6)
      Bleeding 42 (4.4)
      acute renal failure 39 (4.1)
      Others 76 (8.0)
na: not applicable
We also looked at the rate and type of treatment in 
relation to primary tumor site and reason for admisr
sion. Except for thyroid and unknown primary site tur
mors, which were the least primary tumor sites to be 
treated (6.7% and 7.7%, respectively), no difference was 
observed in anemia treatment across different primary 
sites (P=.1831). Treatment rate also varied according to 
reason for admission; only 29 (21.6%) anemic patients 
admitted for chemotherapy were offered any treatment 
compared to a rate of 33.4% for the rest of the cancer 
patients (P=.0075). 
Nearly half of the patients (427, 44.5%) were adr
mitted more than once. The median number of admisr
sions was 1 with a range of 2 to 14 admissions. Among 
the other 532 (55.5%) patients who were admitted 
only once, anemia was found in 409 (76.8%) patients, 
compared to a prevalence of 81% among the 427 par
tients who had multiple admissions (P=.138). Length 
of hospital stay was affected by the presence of anemia; 
the mean hospital stay was 7.27 days (95% CI: 6.95r
7.59) in anemic patients compared to 4.85 days (95% 
CI: 4.59r5.11) among the nonanemics (P<.001). In adr
dition to anemia status, age, reason for admission, prir
mary tumor site and stage were studied for impact on 
length of hospital stay. It was shown that anemia status 
(P<.0001) and primary disease (P<.0001) followed by 
reason for admission (P=.053) were the factors associr
ated with significant impact on length of stay.
DISCUSSION
To our knowledge, this is the first study to address the 
impact on clinical practice of recently published negar
tive studies of ESA when used to prevent or to treat 
anemia in cancer patients. The prevalence of anemia in 
our cancer patients was high: at enrollment, 78.7% of 
patients had hemoglobin levels <12.0 g/dL. The prevar
lence of anemia was even higher (83.0%) when considr
ering all patients in whom low hemoglobin levels were 
recorded at least once during the survey. These rates 
are higher than what previous studies had reported. In 
a large, multinational, prospective survey defining the 
prevalence, incidence and treatment of anemia in cancer 
patients, the European Cancer Anemia Survey (ECAS), 
the prevalence of anemia at enrollment was 39.3%; the 
majority were mild and moderate, while severe anemia 
was reported in only 10% of their patients compared to 
a rate of 16.7% among our study group.19
Though most of patients in our study had mild 
(41.1%) or moderate anemia (42.3%), even at these levr
els of hemoglobin, anemia has a significant impact on 
quality of life and performance status. Although we did 
not compare the symptoms and performance status of 
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Table 2. prevalence and severity of anemia by primary tumor site.
   Primary Disease All patients Anemic patients
Severity of anemia 
Mild Moderate Severe
   gastrointestinal 203 (21.2) 167 (82.3) 71 (42.5) 70 (41.9) 26 (15.6)
   Breast 154 (16.1) 133 (86.4) 49 (36.8) 65 (48.9) 19 (14.3)
   lymphoma/Myeloma 151 (15.7) 122 (80.8) 47 (38.5) 48 (39.3) 27 (22.1)
   lung 106 (11.1) 85 (80.2) 33 (38.8) 37 (43.5) 15 (17.6)
   genitourinary (gU) 77 (8.0) 61 (79.2) 30 (49.2) 19 (31.1) 12 (19.7)
   Head and neck 63 (6.6) 45 (71.4) 18 (40.0) 20 (44.4) 7 (15.6)
   gynecological (gYn) 48 (5.0) 42 (87.5) 12 (28.6) 25 (59.5) 5 (11.9)
   Thyroid 43 (4.5) 15 (34.9) 11 (73.3) 4 (26.7) 0
   Bone and soft tissue sarcoma 42 (4.4) 31 (73.8) 14 (45.2) 12 (38.7) 5 (16.1)
   Brain 38 (4.0) 26 (68.4) 13 (50.0) 9 (34.6) 4 (15.4)
   Unknown primary 17 (1.8) 13 (76.5) 6 (46.2) 6 (46.2) 1 (7.7)
   Others 17 (1.8) 15 (88.2) 6 (40.0) 4 (26.7) 5 (33.3)
   Total 959 (100) 755 (78.7) 310 (41.1) 319 (42.3) 126 (16.7)
Values are n (%).
Table 3. prevalence and severity according to reason for admission.
   Reasons for admission All patients Anemic
Severity of anemia
Mild Moderate Severe
   Chemotherapy 217 (22.6) 134 (61.8) 72 (53.7) 46 (34.3) 16 (11.9)
   infection 190 (19.8) 172 (90.5) 56 (32.6) 74 (43.0) 42 (24.4)
   Supportive care (palliative) 145 (15.1) 121 (83.4) 52 (43.0) 55 (45.5) 14 (11.6)
   arF and electrolyte imbalance 71 (7.4) 58 (81.7) 21 (36.2) 30 (51.7) 7 (12.1)
   Bleeding 42 (4.4) 41 (97.6) 12 (29.3) 17 (41.5) 12 (29.3)
   initial staging and work up 28 (2.9) 21 (75.0) 10 (47.6) 10 (47.6) 1 (4.8)
   Others 266 (27.7) 208 (78.2) 87 (41.8) 87 (41.8) 34 (16.3)
   Total 959 (100) 755 (78.7) 310 (41.1) 319 (42.3) 126 (16.7)
Values are n (%). arF: acute renal failure.
Table 4. rate and type of treatment by severity of anemia.
   Severity of anemia All patients Treated 
Type of treatment
Blood transfusion Supplements ESA Combination
   Mild 310 (41.1) 16 (5.0) 5 (31.2) 8 (50.0) 3 (18.8) 0
   Moderate 319 (42.3) 102 (32.9) 73 (71.6) 16 (15.7) 5 (4.9) 8 (7.8)
   Severe 126 (16.7) 119 (94.4) 110 (87.3) 1 (0.8) 0 8 (6.3)
   Total 755 (100) 237 (31.4) 188 (79.3) 25 (10.5) 8 (3.4) 16 (6.7)
Values are n (%).
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patients in relation to severity of anemia, many previous 
studies have addressed this issue and showed a direct 
relationship between low hemoglobin level, fatigue and 
poor performance status.20r22
The rate of anemia treatment in our group was low 
(21.6%), specifically in the in the group of patients unr
dergoing active treatment with chemotherapy, in whom a 
higher treatment rate is expected. Several reasons might 
have contributed to our findings of high prevalence and 
low treatment rates among hospitalized cancer patients. 
ESAs were the standard treatment for anemic patients 
with cancer on active treatment or even on supportive 
care.23 However, many recent reports and randomized 
studies raised many concerns about the safety of such 
an approach. Many of studies were terminated early 
because of higher early mortality in the ESArtreated 
group. Following these findings, the United States 
Food and Drug Administration announced revisions 
and a warning to restrict ESA indications.24 In response 
to these concerns and warnings, many physicians and 
medical centers refrained from using ESA. This was 
very evident in our study where ESA was used in only 
8 of 237 (3.4%) treated patients. Additionally, the conr
cerns about safety of transfusion as a treatment modalr
ity had kept 68% of the patients in the moderate anemia 
group (Hb: 8.0r9.9 g/dL) without treatment. Luckily, 
this concern was not an issue in the severe anemia group 
(n=126) where 94% were treated, mostly with blood 
transfusion (87%).
Given these concerns in offering ESA or even blood 
transfusion, every effort should be made to identify the 
etiology of anemia. Treatment should be directed to the 
underlying cause. Unfortunately, only in a minority of 
such patients can a specific causative factor be identified 
and directed therapeutic intervention offered. Thus, 
blood transfusion will continue to be the mainstay of 
treatment especially for patients with symptomatic 
anemia, severe hemolysis or bleeding who require rapid 
correction of their hemoglobin and an increase in blood 
volume. However, one should remember that the effect 
of transfusion is shortrlived and may be associated, on 
rare occasions, with potentially serious complications.
The American Society of Hematology and the 
American Society of Clinical Oncology responded posr
itively to these concerns and recently issued common 
guidelines addressing when and how to treat cancer and 
chemotherapyrrelated anemia.25,26 In these guidelines, 
the use of ESA was restricted to patients with cancer 
on active treatment without curative intent. The routine 
use of ESA in cancer patients in whom cure is the prir
mary objective was strongly discouraged. Additionally, 
both societies recommended against the use of these 
products in cancer patients not on active cancer therar
py. Blood transfusion was suggested to be the treatment 
modality for cancer patients with a hemoglobin level 
below 8.0 g/dL. Until further data becomes available, 
these guidelines should be strictly followed.
More recently, safety concerns regarding ESA were 
evaluated in a metaranalysis of controlled ESA oncolr
ogy trials.27 The 60 studies analyzed included 15 323 
patients and were conducted in the settings of chemor
therapy, radiotherapy or combined therapy and anemia 
of cancer. The authors concluded that ESA use did not 
significantly affect mortality (60 studies: OR=1.06; 
95% CI: 0.97r1.15) or disease progression (26 studr
ies: OR=1.01; 95% CI: 0.90r1.14), but increased the 
risk for venousrthromoboembolic events (44 studies: 
OR=1.48; 95% CI: 1.28r1.72). However, prospectively 
designed, randomized clinical trials are needed to exr
amine ESA safety when used according to the revised 
labeling information.
Our study is not without limitations. The data prer
sented represent the practice at a single institution durr
ing a time when the use of ESA was questioned, and 
such practice may not be the same at other institutions 
at a different time interval. Large multirinstitutional 
studies are needed to further address these issues.
Given the recent negative ESA studies and FDA 
warnings, anemia is underrrecognized and underrtreatr
ed. Only severe anemia was adequately treated, mostly 
with blood transfusion while ESA were rarely used. 
The majority of patients with moderate anemia were 
not treated, including patients on active chemotherapy. 
Better guidelines addressing anemia management in 
this subgroup of patients are highly needed. 
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